Back

Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy: from gene to treatment Hypertrophic Cardiomyopathy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Milind Desai

Cleveland Clinic, Cleveland (United States of America)

7 More presentations in this session

Presentation thumbnail
Physical activity measured by accelerometry in hypertrophic cardiomyopathy: findings from the AFFECT-HCM study
Doctor S. Schoonvelde (Rotterdam, NL)
Abstract Slides
Presentation thumbnail
Re-classification of hypertrophic cardiomyopathy genetic variants in patients from the sarcomeric human cardiomyopathy registry (SHaRe)
Ms S. Hespe (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Minimally invasive electro septal myectomy for hypertrophic obstructive cardiomyopathy via right infra-axillary incision
Professor Y. Cui (Hangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials
Doctor C. Kramer (Charlottesville, US)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
Doctor S. Saberi (Ann Arbor, US)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy: from gene to treatment
Video

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM
thumbnail
Congress Presentation
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials
thumbnail
Congress Presentation
Effect of Mavacamten on left ventricular diastolic function and left atrial function in obstructive hypertrophic cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources